SỬA NHÀ GIÁ RẺ THÁI NGUYÊN

Raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. Syros Pharmaceuticals’ stock was trading at $3.59 at the beginning of 2023. Since then, SYRS stock has decreased by 16.7% and is now trading at $2.99.

• Upgrade to MarketBeat All Access to add more stocks to your watchlist.
• Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
• Insiders that own company stock include Eric R Olson, Eric R Olson, Mark J Alles, Richard A Young, Srinivas Akkaraju and Timothy Tyson.
• According to 5 analysts, the average rating for SYRS stock is “Strong Buy.” The 12-month stock price forecast is $32.8, which is an increase of 947.92% from the latest price.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

The latest trend in earnings estimate revisions may not translate into furthe… © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

Recently Viewed Tickers

From media and technology to finance and real estate, leagues and teams across the globe have matured into far more than just back page entertainment. And the decisions they make have huge consequences, not just for the bottom line, but for communities, cities, even entire countries. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareSYRS’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

Syros Pharmaceuticals, Inc. – common stock (SYRS): Price and Financial Metrics

The consensus among Wall Street equities research analysts is that investors should “buy” SYRS shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. The company was founded in 2011 and is based in Cambridge, Massachusetts.

Price Target and Rating

Other market data may be delayed by 15 minutes or more. Syros Pharmaceuticals, Inc. delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the s… Syros Pharmaceuticals, Inc. delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022.

Data may be intentionally delayed pursuant to supplier requirements. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Verify your identity, personalize the content you receive, or create and administer your account.

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Only 7 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days. MarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 1 article on an average week. Syros Pharmaceuticals has received a 71.05% net impact score from Upright.

One share of SYRS stock can currently be purchased for approximately $2.99. 48.77% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. 12.79% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Syros Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Syros Pharmaceuticals has a short interest ratio (“days to cover”) of 5.5. Syros Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.

Price and EPS Surprise Chart

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Syros Pharmaceuticals in the last twelve months.

This popular ETF stands apart from its peers with unusually large ownership of many stocks in its compact portfolio. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Syros Pharmaceuticals Inc. 52 week high is $11.50 as of April 28, 2023.

The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Syros Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101.

Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company.

Bloomberg Markets The Close Romaine Bostick breaks down the day’s top stories and trading action leading into the close. The 3 year net cashflow from operations growth rate now stands at -84.69%. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Provide specific products and services to you, such as portfolio management or data aggregation. We’d like to share more about how we work and what drives our day-to-day business. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns.

Financial Forecast

In the past three the similarities between day trading and gamblings, Syros Pharmaceuticals insiders have not sold or bought any company stock. Only 2 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Right-click on the chart to open the Interactive Chart menu. Market flag for targeted data from your country of choice. For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more.

https://1investing.in/– Potential beginning of the bullish trendFollow me and smash that like button! Bio-pharmaceutical company aims to treat cancer and genetic diseases. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.

The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The volatility of SYROS PHARMACEUTICALS INC’s share price is greater than that of 92.92% US stocks with at least 200 days of trading history. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.

JMP Securities analyst Jason Butler reiterated a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $16.00. The company’s shares closed today at $3.50.Butler covers the Healthcare … We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia . The average analyst rating for SYRS stock from 5 stock analysts is “Strong Buy”. This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.